Agonistic antibodies and TREM2-boosting compounds are being investigated to enhance microglial resilience in diseases such as Alzheimer’s and Parkinson’s (Dhapola et al., 2021; Xue et al., 2024). Here, TREM2 is linked to Parkinsonism.